Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Viridian Therapeutics Signs $70M Upfront Licensing Deal With Kissei For Veligrotug And VRDN-003 iIn Japan, With Up To $315M In Milestones

Author: Benzinga Newsdesk | July 30, 2025 03:21am

Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan -
Viridian to receive an upfront payment of $70 million -
Additionally, Viridian is eligible to receive up to an additional $315 million in development, regulatory, and commercial milestone payments as well as tiered royalties on net sales in Japan in the 20s to mid-30s percent -
Collaboration combines Viridian's potential best-in-class portfolio in thyroid eye disease with Kissei's development and commercialization expertise in rare diseases in Japan -

Posted In: VRDN